
    
      This is a randomized, single-blind, placebo-controlled, single-center, phase 1 study to
      assess the safety, tolerability, pharmacokinetics, pharmacodynamics and the effect of fasting
      after single ascending oral doses of AZD5658 in type 2 diabetes mellitus patients.
    
  